
ZBIO Stock Forecast & Price Target
ZBIO Analyst Ratings
Bulls say
Zenas BioPharma is supported by a compelling obexelimab profile that combines flare prevention, a reversible non-depleting CD19/FcγRIIb mechanism, and meaningful steroid-sparing effects, including a week 52 glucocorticoid toxicity score improvement versus placebo of -11.4 (p=0.021). The INDIGO open-label extension also showed strong durability, with 12-month flare-free probabilities of 93% and 87%, while early vaccine data suggested preserved responsiveness in 6/7 influenza and 4/4 COVID-19 participants during a treatment-free window. Fundamentally, the stock appears attractive because IgG4-RD remains a chronic, relapsing disease with large unmet need, rising diagnosis, and a substantial commercial opportunity, while obexelimab’s at-home weekly dosing and differentiation from B-cell depleters could support adoption ahead of the May 27, 2027 PDUFA.
Bears say
Zenas BioPharma is a clinical-stage biopharmaceutical company whose outlook is pressured by heavy dependence on obexelimab, a lead asset that may fail to demonstrate efficacy, produce inconvenient dosing intervals, or trigger safety signals that could halt development. The company also faces meaningful regulatory risk, as delays could reduce market uptake and financing flexibility, while commercial competition from current and future therapies could further limit adoption. With management focused on a single reportable segment and no diversified revenue base cited, an inability to achieve sales estimates would leave the company highly exposed to clinical and commercialization setbacks.
This aggregate rating is based on analysts' research of Zenas Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ZBIO Analyst Forecast & Price Prediction
Start investing in ZBIO
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Zenas Biopharma Inc (ZBIO) Forecast
ZBIO Analyst Forecast & Price Prediction
Start investing in ZBIO
Order type
Buy in
Order amount
Est. shares
0 shares